Background: Little has been written about the utility of thoracic electrical bioimpedance
(TEB)-derived cardiac physiologic variables in evaluating patients with low-risk chest pain syndromes.
The EXT-TEBCO[TM] Module measures Cardiac Index, Stroke Index, Heart Rate, Respiratory Rate, and six other cardiodynamic parameters using Thoracic Electrical Bioimpedance
com(TM), use Thoracic Electrical Bioimpedance
(TEB) technology to obtain data which is typically available only through the time-consuming, costly and potentially dangerous invasive Pulmonary Artery Catheterization (PAC) procedure.
com, the world's smallest, most cost-effective, full-featured Thoracic Electrical Bioimpedance
LIFEGARD II with ICG (Impedance CardioGraphy) uses Thoracic Electrical Bioimpedance
(TEB) to measure continuous cardiac output, and is the only patient monitor that has ICG totally integrated with all other standard, non-invasive vital signs.
ICG is based on enhanced thoracic electrical bioimpedance
technology, which allows a simple, quick, and easy method for clinicians to perform hemodynamic assessment or continuous monitoring of a patient's hemodynamic status.
Perry, chief executive officer of CardioDynamics, stated, "One of the major benefits of the BioZ's proprietary Thoracic Electrical Bioimpedance
(TEB) technology is its usefulness in a vast range of applications.
The study demonstrates that CardioDynamics' proprietary noninvasive Thoracic Electrical Bioimpedance
(TEB) technology can significantly reduce healthcare expenditures by providing an alternative to the costly, risky and invasive Pulmonary Artery Catheter (PAC).
The studies further validated that CardioDynamics' proprietary noninvasive Thoracic Electrical Bioimpedance
(TEB) technology accurately measures cardiac output as compared to measurements by Intermittent Bolus Thermodilution (IBTD) from a Pulmonary Artery Catheter (PAC), as well as the long standing "gold standard," Direct Fick.
The studies demonstrated that CardioDynamics' proprietary Thoracic Electrical Bioimpedance
(TEB) technology accurately and inexpensively measures cardiac performance in both hospital critical care units and outpatient physician office settings.
The company credited the strong second quarter sales growth to the focused sales efforts of its domestic sales force and international distributor network, the positive effects of Health Care Financing Administration's (HCFA) decision mandating full nationwide Medicare reimbursement coverage, and the growing healthcare community's recognition of the validity and clinical usefulness of the BioZ's Thoracic Electrical Bioimpedance
com(TM) utilize its proprietary Thoracic Electrical Bioimpedance
(TEB) technology to noninvasively obtain data on a wide range of hemodynamic parameters.